Radioimmunoassay and Biomarkers Core

放射免疫分析和生物标志物核心建议继续提供越来越多的高- 高质量的免疫分析和生化服务，我们不断发展的糖尿病研究中心（DRC）的基本， 翻译和临床科学家。上一个周期的服务包括放射免疫测定， 酶联免疫吸附测定（ELISA），Luminex平台上的多重ELISA，高效液相色谱法（HPLC） 在ThermoFisher平台上进行色谱分析（HPLC），在Yellow Springs Instruments上进行代谢物测定 (YSI)平台，以及最近在ELLA平台上的多重ELISA，用于扩大各种糖尿病， 代谢相关的激素、细胞因子和来源于血液、尿液、唾液和组织样品的代谢物。 这些检测服务已被证明对DRC和宾夕法尼亚大学糖尿病研究所当前的研究至关重要， 肥胖和代谢（IDOM），并将继续成为未来运营和发展的一个组成部分， 中心和研究所。在下一个周期，RIA/生物标志物核心将继续现有的免疫测定服务。 包括RIA，这对高样本数实验的成本可行性至关重要，并扩大服务 除了RIA、ELISA、Luminex、HPLC和YSI平台之外，还包括在更灵敏的 基于微流控ELISA（ELLA）的多重平台。ELLA技术将用于实现精确的 具有增强的灵敏度和扩展的动态范围的细胞因子的多路复用 在啮齿动物和人类研究中炎症和代谢的交叉，因此提高了我们的价值。 为刚果民主共和国调查人员扩大化验服务。此外，核心小组还将积极主动地开展外联活动， 当地的糖尿病研究社区，肥胖和代谢研究人员，同时加强质量保证/质量控制/质量管理 提供的化验服务。此外，RIA/生物标志物核心将整合新的和现有的 通过Smilow中心内的共享资源，为不断扩大的研究人员提供分析服务， 翻译研究。核心位于IDOM的12楼，靠近胰岛细胞 生物学、功能基因组学和啮齿动物代谢表型核心，促进 这些DRC核心通过以下措施，将加强核心中心提供的化验服务的综合交付： 开发信息基础设施，以便使用iLab订购、跟踪、计费和交付服务。的 在中央核心设施而不是分散的地点进行大量RIA和ELISA 在整个大学提供了一个显着的整体节省设备，人员的努力，和用品， 我们的研究人员，同时重要的是，由于我们的增强， 质量控制/质量保证/质量管理（QA/QC/QM）流程。我们将继续合作 与其他NIH赞助的核心资源和宾夕法尼亚大学医学院合作， 为我们的调查人员提供的服务数量，提高提供服务的效率和技术专长 我们将继续致力于提高我们的分析服务的质量，并继续提高我们的通量和数据质量。

The Radioimmunoassay and Biomarkers Core proposes to continue offering an increasing number of high- quality immunoassay and biochemistry services to our evolving group of Diabetes Research Center (DRC) basic, translational, and clinical scientists. Services over the last cycle have included radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), multiplex ELISA on the Luminex platform, high performance liquid chromatography (HPLC) on the ThermoFisher platform, metabolite assays on the Yellow Springs Instruments (YSI) platform, and most recently multiplex ELISA on the ELLA platform for an expanding variety of diabetes and metabolism related hormones, cytokines, and metabolites derived from blood, urine, salivary and tissue samples. These assay services have proven essential for current research in the DRC and Penn’s Institute for Diabetes, Obesity & Metabolism (IDOM) and will remain an integral part of the future operation and development of the Center and Institute. In the next cycle the RIA/Biomarkers Core will continue existing immunoassay serives including RIA that are essential for cost feasibility of high sample number experiments, and expand services beyond RIA, ELISA, Luminex, HPLC, and YSI platforms to include development of assays on a more sensitive multiplex platform based on microfluidic ELISA (ELLA). ELLA technology will be used to implement accurate multiplexing of cytokines with enhanced sensitivity and an expanded dynamic range required for understanding the intersection of inflammation and metabolism in rodent and human studies, and so enhance the value of our expanding assay services for DRC investigators. In addition, the Core will proactively engage in outreach to the local research community of diabetes, obesity and metabolism investigators, while enhancing the QA/QC/QM of the assay services provided. In addition, the RIA/Biomarkers Core will integrate delivery of new and existing assay services to an expanding base of investigators via shared resources within the Smilow Center for Translational Research. The Core is located on the 12th floor in IDOM and in near proximity to the Islet Cell Biology, Functional Genomics, and Rodent Metabolic Phenotyping Cores that fosters close interactions among these DRC Cores. The integrated delivery of assay services provided by the Core will be enhanced by further development of informatics infrastructure for ordering, tracking, billing and delivery of service using iLab. The performance of a large number of RIAs and ELISAs in a central core facility rather than in scattered locations throughout the University provides a significant overall savings in equipment, personnel effort, and supplies for our investigators, while importantly allowing for the generation of results with better quality due to our enhanced quality control/quality assurance/quality management (QA/QC/QM) processes. We will continue collaborations with other NIH-sponsored core resources and the School of Medicine at Penn in order to enhance and expand the number of services available to our investigators, increase efficiency and technical expertise in the provision of assay services, and continue to improve our throughput and data quality.